SK Biopharm's CTO On Diversity In Open Innovation
Primarily Looking At Oncology, CNS Collaborations
SK Biopharm’s chief technology officer outlines how the company’s open innovation strategy may vary and what he sees as essential in new drug development.
You may also be interested in...
The CNS-focused SK Group affiliate has set out ambitious growth plans for this year and is moving forward with a diversification into oncology and other areas, beginning its first US cancer trials in brain tumors and cancers with brain metastasis.
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.